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Abstract: Inflammasomes are large multi-protein complexes that control host defense and inflammation
during infections with pathogens. Their clinical importance however reaches beyond infectious disease, since
dysregulated inflammasome activity has also been linked to many auto-inflammatory disorders. This article
gives a short overview on the basics of inflammasome signaling, their activation mechanisms and their role in
autoimmunity.
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The innate immune system provides
the first line of defense against invading
pathogens by initiating the onset of the
inflammatory response, which promotes
pathogen removal and restores tissue ho-
meostasis. A critical step is to first detect
the presence of a pathogen in the host or-
ganism. This is achieved by so-called pat-
tern-recognition receptors (PRRs), which
monitor the extra- and intracellular com-
partments of host cells for the presence
of pathogens. PRRs recognize conserved
microbial molecules known as pathogen-
associated molecular patterns (PAMPs)
that are generally only made by microbes
and not host cells thus allowing a distinc-
tion between self and non-self.
[1]
At the
same time, PRRs also detect the presence
of mislocalized self-molecules, like DNA
or certain cytosolic proteins, which act as
indicators of cellular damage or stress and
are thus referred to as danger-associated
molecular patterns (DAMPs).
The first group of PRRs that was
characterized were the Toll-like receptors
(TLRs), transmembrane proteins that de-
tect PAMPs and DAMPs in the extracel-
lular compartment or within endosomes.
[2]
Ligand recognition by TLRs results in the
initiation of conserved signaling pathways
leading to the production of inflammatory
cytokines and interferons; signaling mol-
ecules that induce inflammation and co-
ordinate anti-microbial host defense reac-
tions. Many successful pathogens, among
them viruses and bacteria, however do not
reside extracellularly but invade and rep-
licate within host cells. Thus the host cell
cytosol also features a diverse set of PRRs.
Notable among these are receptors that
do not induce a transcriptional response,
but initiate the assembly of large signal-
ing complexes commonly referred to as
inflammasomes (Fig. 1).
Inflammasomes are assembled by
members of the NOD-like receptors
(NLR), PYD-, and HIN- domain contain-
ing (PYHIN) proteins family and TRIM-
family members. These proteins are char-
acterized by distinct functional domains
that participate in ligand sensing, oligo-
merization, and the recruitment of down-
stream signaling components.Assembly of
an inflammasome involves ligand-induced
activation of the receptor protein, followed
by self-oligomerization and the exposure
of signaling domains, which can be either a
PYD (Pyrin Domain) or a CARD (Caspase
Recruitment Domain).
[3]
This results in the
recruitment of a small signaling adaptor
protein called ASC, which consists only
of a PYD and CARD. ASC is unique in
its function, in that upon recruitment to
activated receptors, it starts to oligomer-
ize into long helical filaments via its PYD,
which expose its CARD at their surface.
[4]
This step acts as a signal amplification
mechanism since it allows a single receptor
oligomer to initiate the generation of large
number of freely exposedCARDs in a short
time.
[5]
These free CARDs are important
for the recruitment of pro-caspase-1, the
inactive form of the inflammasome effec-
tor protease caspase-1. Dimerization and
auto-proteolysis results in the generation
of a catalytically active caspase-1 hetero-
tetramer, which is released from the com-
plex and mediates downstream signaling.
Active caspase-1 is an effective prote-
ase and has been shown to cleave a num-
ber of target proteins to exert its biological
function. Over the years two main out-
comes have been characterized in detail,
which are the proteolytic maturation and
release of certain cytokines and the induc-
tion of a lytic inflammatory cell death,
called pyroptosis.
[6]
Proteolytic maturation
of cytokines is a well-recognized function
of caspase-1 and indeed the protease was
initially identified as ICE (Interleukin-
converting enzyme),
[7]
since it was respon-
sible for cleaving the biologically inactive
pro-form of interleukin (IL)-1β (pro-IL-
1β) into its mature, secreted form. IL-1β is
a major driver of inflammation in the body,
and responsible for activating immune
cells and recruiting them to the site of in-
fection. The second function of caspase-1,
which is the induction of cell death was
identified later, but has also been shown to
play an important role in host defense.
[8]
Pyroptosis effectively kills the infected
cells, thus preventing further intracellu-
lar replication of pathogens while at the
same time exposing them to extracellular
immune mechanism such as the comple-
ment system and antibodies. The mecha-
nism by which caspase-1 induces pyropto-
sis has been recently identified; cleavage
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to host health. This is evident in a group
of auto-inflammatory disorders known as
‘inflammasomopathies’ caused by activat-
ing mutations in inflammasome-forming
receptors.
[11]
Patients suffering from these
disorders, including Cryopyrin-Associated
Periodic Syndromes (CAPS), Familial
Mediterranean Fever (FMF) and macro-
phage activation syndrome (MAS) expe-
rience common symptoms such as fever,
rash and sterile inflammation, which are
instigated by spontaneous macrophage
activation and release of the pyrogenic
cytokines IL-1β and IL-18. Furthermore,
uncontrolled inflammasome activation has
been linked to a number of acquired auto-
inflammatory diseases, such as gout, pseu-
dogout, asbestosis, silica-mediated pulmo-
nary disorder, atherosclerosis and type II
diabetes mellitus. Common to these disor-
ders is that sterile inflammatory triggers,
such as uric acid crystals or cholesterol
crystals, initiate inflammasome assembly
and excess release of IL-1β and inflamma-
tion.
Neutralization of the inflammasome
thus offers considerable therapeutic prom-
ise to reduce detrimental inflammation
in inflammasome-related disorders and
of nuclear DNA. Pathogens can however
also be detected indirectly, by detecting
the damage caused to host cells or the ef-
fects of microbial effector proteins. An
ingenious mechanism is employed by
NLRP1B, which acts as a pseudo-substrate
for Lethal Factor (LF) of B. anthracis, a
protease that normally shuts down innate
immune signaling. LF-mediated cleavage
of NLRP1B however activates the propen-
sity of the protein to assemble inflamma-
somes. Pyrin, another of these receptors,
can sense the microbe-induced modifica-
tion of host Rho GTPases, but the mecha-
nism is still unknown, as is the mechanism
of NLRP3 activation, a sensor that recog-
nizes pathogens as well as a number of
sterile inflammatory stimuli.
Consistent with their specificity for
microbial ligands, inflammasomes have
been shown in countless animal studies to
provide essential protection for the host
against viral, bacterial, fungal and even
protozoan pathogens. Given the potency
of this system, it is hardly surprising that
inflammasome assembly needs to be high-
ly regulated,
[3]
and consistently it has been
found that unscheduled and dysregulated
inflammasome activation is detrimental
of a single protein substrate known as
Gasdermin-D is sufficient to induce py-
roptosis.
[9]
This processing event results
in the generation of an N-terminal part of
Gasdermin-D, which turns out to be highly
cytotoxic. How exactly Gasdermin-D kills
the cell is still being investigated, but we
and other have shown that the N-terminal
part of Gasdermin-D can form plasma
membrane pores, which presumably result
in a rapid loss of the electrochemical gradi-
ent and osmotic lysis of the cell.
The main function of inflammasome is
to detect pathogens, and this is highlighted
by the vast array of microbial ligands that
are detected by inflammasome-forming re-
ceptors.
[10]
The best studied among these
is NLRC4, which detects bacterial flagel-
lin and several structural components of
bacterial type 3 secretion systems (T3SS)
through partner proteins known as NAIPs,
which directly bind these ligands. Direct
ligand binding has also been demonstrated
for the receptor AIM2, which features a
DNA-binding HIN domain and assembles
an inflammasome when detecting DNA in
the cytosol. Cytosolic DNA can be an in-
dicator of a viral or bacterial infection, or
of damage to the host cell and the leakage
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Fig. 1. Schematic representation of inflammasome assembly and signaling. Detection of pathogens or inflammatory stimuli by cytosolic PRRs (e.g.
NLRP1B, NLRP3, NLRC4, AIM2 or pyrin) activates the receptor (purple) and results in its oligomerization. These receptor oligomers recruit the adap-
tor ASC (green), which starts to form filaments through its pyrin domain that expose the second domain of ASC, a caspase recruitment domain, on
their surface. This results in the recruitment of pro-caspase-1 (blue), which gets activated within the complex. Active caspase-1 is released from the
complex and starts to process target proteins. Processing of pro-IL-1β (red) into its mature form by caspase-1 is required for the cytokine to be-
come biologically active. Caspase-1 will in addition induce the processing of Gasdermin-D (gray). Cleavage of Gasdermin-D results in the formation
of a cytotoxic N-terminal fragment of Gasdermin-D, which induces pyroptosis, a lytic inflammatory cell death, that is required for the restriction of
pathogen replication and the release of processed IL-1β.
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inherited autoinflammatory disorders.
Anti-IL-1β therapies such as Anakinra
(IL-1-receptor antagonist) have been suc-
cessfully used in the treatment for gout for
example, but such therapies are often very
costly. Recent studies however have high-
lighted the potential of small-molecule in-
hibitors of NLRP3 in regulating inflamma-
some signaling in mouse models of CAPS
and experimental autoimmune encephalo-
myelitis (EAE).
[12]
Thus understanding the
molecular mechanism of how inflamma-
somes are assembled and signaled could
be instrumental in the identification of
new therapeutic targets and could foster
the development of new anti-inflammato-
ry therapies for inflammasome-associated
diseases based on a range of selective in-
hibitors of individual inflammasomes.
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